Elotuzumab

Drug Profile

Elotuzumab

Alternative Names: BMS-901608; Empliciti; HuLuc63; PDL063

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD319 antigen modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 07 Sep 2017 US FDA places a partial clinical hold on a phase II trial Multiple Myeloma (Combination therapy, second-line therapy or greater) based on risks identified in trials studying another anti–PD-1 agent, pembrolizumab, in patients with multiple myeloma (NCT02612779)
  • 07 Sep 2017 US FDA places a partial clinical hold on the CheckMate-602 trial based on risks identified in trials studying another anti–PD-1 agent, pembrolizumab, in patients with multiple myeloma
  • 07 Aug 2017 Bristol-Myers Squibb initiates enrolment in a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Finland (IV) (NCT03155100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top